CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation-Reference-Cited by-同舟云学术

CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation

Published:2022-08 Issue:8 Volume:24 Page:841-849
ISSN:1465-3249
Container-title:Cytotherapy
language:en
Short-container-title:Cytotherapy

Author:

Yan Nan,Wang Na,Wang Gaoxiang,Huang Liang,Li Chunrui,Wang Di,Wang Jue,Huang Lifang,Meng Fankai,Wei Jia,Chen Liting^ORCID,Mao Xia,Zhou Jianfeng,Zhang Yicheng,Cao Yang^ORCID

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Cancer Research,Transplantation,Cell Biology,Genetics (clinical),Oncology,Immunology,Immunology and Allergy

Reference48 articles.

1. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

2. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT;Spyridonidis;Leukemia,,2012

3. Donor lymphocyte infusions: the long and winding road: how should it be traveled?;Tomblyn;Bone Marrow Transplant,2008

4. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation;Collins;J Clin Oncol,1997

5. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation;Loren;Bone Marrow Transplant,2008

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving the safety of CAR‐T‐cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B‐cell lymphoma undergoing CAR‐T‐cell therapy;American Journal of Hematology;2024-01-10

2. Blood–brain barrier breakdown, central nervous system cell damage, and infiltrated T cells as major adverse effects in CAR-T-related deaths: a literature review;Frontiers in Medicine;2024-01-08

3. CAR T-Cells in Acute Lymphoblastic Leukemia: Current Status and Future Prospects;Biomedicines;2023-10-02

4. Searching for the optimal sequence of dual-targeted CAR T cells in relapsed/refractory acute lymphoblastic leukemia;Chinese Clinical Oncology;2023-08

5. Are we ready for personalized CAR‐T therapy?;European Journal of Haematology;2023-07-11